FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 303:718-722 September 25, 1980 Number 13 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To detect early relapse in the central nervous systems (CNS) of patients with acute leukemia or lymphoma, we measured levels of beta 2-microglobulin (beta 2 m) in serum and cerebrospinal fluid (CSF). CSF levels were significantly higher in patients with leukemia (P < 0.001) or lymphoma (P < 0.02) with clinical evidence of CNS involvement than in those without this complication. When serum and CSF levels were measured simultaneously, the CSF level of beta 2 m was significantly higher than the serum level in patients with acute leukemia and lymphoma with CNS involvement (P = 0.05), but not in patients without CNS involvement. Serial determination of CSF beta 2 m correlated well with the clinical appearance and disappearance of CNS involvement. These data suggest that serial and simultaneous determination of beta 2 m in serum and CSF may be useful in early diagnosis of CNS involvement and in monitoring intrathecal therapy in patients with acute leukemia or lymphoma.

This article has been cited by other articles:

• Ernerudh, J., Olsson, T., Berlin, G., von Schenck, H. (1987). Cerebrospinal Fluid Immunoglobulins and {beta}2-Microglobulin in Lymphoproliferative and Other Neoplastic Diseases of the Central Nervous System. Arch Neurol 44: 915-920 [Abstract]  
• Stern, B. J., Krumholz, A., Johns, C., Scott, P., Nissim, J. (1985). Sarcoidosis and Its Neurological Manifestations. Arch Neurol 42: 909-917 [Abstract]